Boule Diagnostics

Interim Report
Q2 2021

Strong sales growth

We are finally starting to see clear signs of recovery in the market. Reduced spread of virus and increasing vaccination rates have eased restrictions in several markets and communities are starting to open up. The US is our market that has come the furthest, with stable sales at a normal level. Increased instrument sales in individual countries in Asia and good growth in the OEM business resulted in a sales increase of 22 percent, corresponding to an increase of 34 percent in constant currencies.

Strong instrument sales in Asia confirm our market position while sending a very positive signal that the market expects a return to more normal patient and testing flows. Demand for instruments has exceeded our supply capacity during the quarter, which has been reduced due to supply chain disruptions, forcing us to delay some customer deliveries.

 

Financial Highlights

NET SALES, MSEK

111

GROSS MARGIN

41,7 %

OPERATING PROFIT, MSEK

2.3

OPERATIONAL CASH FLOW, MSEK

8.2

Net sales by region

Created with Highcharts 9.2.2USA (34.4%)Asia (28.2%)Eastern Europe (13.1%)Latin America (7.0%)Africa, Middle East (10.6%)Western Europe (6.7%)

Net sales by product

Created with Highcharts 9.2.2Consumables, own instruments (39.4%)Instruments (32.3%)Consumables, OEM and CDS brand (21.6%)Other (6.7%)

Near-patient diagnostics

Complete Blood Count (CBC) is the most common test for in vitro diagnostics. In 2019, the decentralized and patient-related hematology segment had an estimated market value of just over SEK 6 billion, while the corresponding segment for the veterinary market was valued at approximately SEK 2.6 billion

100 +

Countries

SEK 9 billion

Human and veterinary market

130 miljoner

Tests per year

About Boule Diagnostics

Boule Diagnostics AB is a global diagnostics company specializing in near-patient, decentralized blood diagnostics and one of the few companies in the global diagnostics market that conducts its own development, manufacturing and marketing of instruments and consumables for blood diagnostics. The Company primarily serves hospitals, clinics, laboratories and other diagnostics companies.